Preview

Problems of Endocrinology

Advanced search

NPH insulin. Effective mixing - effective dose regimen

https://doi.org/10.14341/probl201157456-60

Abstract

Insulin therapy, a corner stone of the treatment of diabetes mellitus, both type 1 and type 2, has undergone substantial modification since the manufacture of the first insulin preparations 90 years ago up to the present time. Human insulins, such as neutral protamin Hagedorn (NPH) insulins, remain a major instrument of therapy of diabetes mellitus despite rapid developments in this field of knowledge and the wide availability of insulin analogs. When prescribing these preparations, the attending physician should be absolutely confident that the patient has a minimum background of knowledge and skills indispensable for efficacious and safe treatment. Such skills include the habit of mixing NPH insulin suspensions by 20-fold turning the vial or the cartridge upside-down or rolling them between the palms in order to ensure the uniform distribution of insulin in the suspension and its accurate dosing. The manufactures place from one to three glass or metal bullets inside the vials and cartridges for more homogeneous mixing of their contents. P. Kaiser et al. undertook the study of several pharmaceutical forms of NPH insulin manufactured by different companies to estimate the accuracy of dosing (variability of the insulin dose depending on the number of turns of the cartridge for homogeneous mixing). The insulin concentration in a single dose was measured by high-performance liquid chromatography. Marked variability of the insulin dose after less than ten (three or six) turns was documented for all cartridges with the exception of Insuman Basal insulin cartridges ("Sanofi"). It may be expected that the accuracy of dosing will not deteriorate using these cartridges owing to the presence in them of three heavy metal bullets even if the patient does not perform the necessary mixing procedure for one or another reason.

About the Author

T V Nikonova



References

1. Brostoff J.M., Keen Н., Brostoff J. A diabetic life before and after insulin era. Diabetologia 2007; 50: 1351-1353.

2. Alberti G. Lessons from the history of insulin. Diabetes Voice 2001; 46: 33-34.

3. Ozawa H., Murai Y., Ozawa T. A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus. Yakushigaku Zasshi 2003; 38: 1-27.

4. Laubach E., Schwandt P., Ritter M.M. Neutral protamine Hagedorn insulin. Lancet 2000; 355: 236.

5. Murnaghan J.H., Talalay P. John Jacob Abel and the crystallization of insulin. Persp Biol Med 1967; 10: 334-381.

6. Балаболкин М.И., Клебанова E.M., Креминская B.M. Лечение сахарного диабета и его осложнений. Медицина 2005; 512.

7. Heinemann L., Sinha К., Weyer С. et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 1999; 16: 332-338.

8. Scholtz H.E., Pretorius S.G., Wessels D.H., Becker R.H. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using an euglycaemic clamp technique. Diabetologia 2005; 48: 1988-1995.

9. American Diabetes Association. Clinical practice recommendations. Diabetes Care 2009; 32: Suppl l: l-98.

10. Bantle J.P., Neal L., Frankamp L.M. Effects of the anatomical region used for insulin injections on glycemia in type 1 diabetes subjects. Diabetes Care 1993; 16: 1592-1597.

11. Thow J.C., Johnson A.B., Fulcher G., Home P.D. Different absorption of isophane (NPH) insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique. Diabet Med 1990; 7: 600-602.

12. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002; 4: 673-682.

13. Hänel H., Weise A., Sun W. et al. Differences in the dose accuracy of insulin pens. J Diabetes Sci Technol 2008; 2: 478-481.

14. Jorgensen J.O., Flyvbjerg A., Jorgensen J.T. et al. NPH insulin administration by means of a pen injector. Diabet Med 1998; 55: 574-576.

15. Fisken R.A., Goulbourn J. Treatment of insulin-dependent diabetes using an injection pen: control, problems and patients preferences. Diabetes Res 1989; 11: 195-197.

16. Jehle P.M., Micheler C., Jehle D.R. et al. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet 1999; 354: 1604-1607.

17. Brown A., Steel J.M., Duncan С. et al. An assessment of the adequacy of suspension of insulin in pen injectors. Diabet Med 2004; 21: 604-608.

18. Kaiser P., Maxeiner S., Weise A. et al. Assessment of the Mixing Efficiency of Neutral Protamine Hagedorn Cartridges. J Diabetes Sci Technol 2010; 4: 652-657.


Review

For citations:


Nikonova T.V. NPH insulin. Effective mixing - effective dose regimen. Problems of Endocrinology. 2011;57(4):56-60. https://doi.org/10.14341/probl201157456-60

Views: 1196


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)